179 related articles for article (PubMed ID: 27502726)
1. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.
Olaussen KA; Postel-Vinay S
Ann Oncol; 2016 Nov; 27(11):2004-2016. PubMed ID: 27502726
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
[TBL] [Abstract][Full Text] [Related]
3. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
[TBL] [Abstract][Full Text] [Related]
4. Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.
Grenda A; Błach J; Szczyrek M; Krawczyk P; Nicoś M; Kuźnar Kamińska B; Jakimiec M; Balicka G; Chmielewska I; Batura-Gabryel H; Sawicki M; Milanowski J
Cancer Med; 2020 Jan; 9(2):605-614. PubMed ID: 31797573
[TBL] [Abstract][Full Text] [Related]
5. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
Rosell R; Felip E; Taron M; Majo J; Mendez P; Sanchez-Ronco M; Queralt C; Sanchez JJ; Maestre J
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4215s-4219s. PubMed ID: 15217961
[TBL] [Abstract][Full Text] [Related]
6. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
Bepler G; Williams C; Schell MJ; Chen W; Zheng Z; Simon G; Gadgeel S; Zhao X; Schreiber F; Brahmer J; Chiappori A; Tanvetyanon T; Pinder-Schenck M; Gray J; Haura E; Antonia S; Fischer JR
J Clin Oncol; 2013 Jul; 31(19):2404-12. PubMed ID: 23690416
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
Heo SJ; Jung I; Lee CK; Kim JH; Lim SM; Moon YW; Shim HS; Jeong J; Kim JH; Kim HR; Cho BC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):539-48. PubMed ID: 26811178
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
Mlak R; Krawczyk P; Ramlau R; Kalinka-Warzocha E; Wasylecka-Morawiec M; Wojas-Krawczyk K; Kucharczyk T; Homa I; Kozioł P; Ciesielka M; Chudziak D; Milanowski J
Oncol Rep; 2013 Nov; 30(5):2385-98. PubMed ID: 23982437
[TBL] [Abstract][Full Text] [Related]
9. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
Ceppi P; Volante M; Novello S; Rapa I; Danenberg KD; Danenberg PV; Cambieri A; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV
Ann Oncol; 2006 Dec; 17(12):1818-25. PubMed ID: 16980606
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.
Reynolds C; Obasaju C; Schell MJ; Li X; Zheng Z; Boulware D; Caton JR; Demarco LC; O'Rourke MA; Shaw Wright G; Boehm KA; Asmar L; Bromund J; Peng G; Monberg MJ; Bepler G
J Clin Oncol; 2009 Dec; 27(34):5808-15. PubMed ID: 19884554
[TBL] [Abstract][Full Text] [Related]
11. Impact of biomarkers on non-small cell lung cancer treatment.
Toschi L; Cappuzzo F
Target Oncol; 2010 Mar; 5(1):5-17. PubMed ID: 20443070
[TBL] [Abstract][Full Text] [Related]
12. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Joerger M; deJong D; Burylo A; Burgers JA; Baas P; Huitema AD; Beijnen JH; Schellens JH
Lung Cancer; 2011 Nov; 74(2):310-7. PubMed ID: 21529986
[TBL] [Abstract][Full Text] [Related]
13. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
Simon GR; Schell MJ; Begum M; Kim J; Chiappori A; Haura E; Antonia S; Bepler G
Cancer; 2012 May; 118(9):2525-31. PubMed ID: 22028294
[TBL] [Abstract][Full Text] [Related]
14. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.
Mlak R; Krawczyk P; Ciesielka M; Kozioł P; Homa I; Powrózek T; Prendecka M; Milanowski J; Małecka-Massalska T
Clin Transl Oncol; 2016 Sep; 18(9):915-24. PubMed ID: 26650486
[TBL] [Abstract][Full Text] [Related]
15. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.
Lv C; Ma Y; Feng Q; Fang F; Bai H; Zhao B; Yan S; Wu N; Zheng Q; Li S; Chen J; Wang J; Feng Y; Wang Y; Pei Y; Fang J; Yang Y
World J Surg Oncol; 2013 Apr; 11():96. PubMed ID: 23621919
[TBL] [Abstract][Full Text] [Related]
16. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.
Bepler G; Kusmartseva I; Sharma S; Gautam A; Cantor A; Sharma A; Simon G
J Clin Oncol; 2006 Oct; 24(29):4731-7. PubMed ID: 16966686
[TBL] [Abstract][Full Text] [Related]
17. The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
Nie X; Cheng G; Ai B; Zhang S
Cancer Biomark; 2013 Jan; 13(6):433-40. PubMed ID: 24595080
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics and gemcitabine.
Rosell R; Cobo M; Isla D; Camps C; Massuti B
Ann Oncol; 2006 May; 17 Suppl 5():v13-16. PubMed ID: 16807441
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Zhao H; Zhang H; Du Y; Gu X
Tumour Biol; 2014 Dec; 35(12):12679-88. PubMed ID: 25227663
[TBL] [Abstract][Full Text] [Related]
20. Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin.
Qiu ZQ; Zhao K
Asian Pac J Cancer Prev; 2014; 15(17):7303-7. PubMed ID: 25227833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
